At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Pazopanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb in Metastatic reNal Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano·interventional·Posted Jul 8, 2020·Updated Jul 10, 2020
In Brief
A Phase 2 clinical trial evaluating Pazopanib for Metastatic Renal Cell Carcinoma. Completed, enrolled 25 participants.
Detailed Summary
This is a prospective, single-arm, monocentric translational study designed to evaluate possible biomarkers of resistance to the first line of therapy with pazopanib in patients with metastatic renal cell carcinoma (mRCC) who have not received systemic therapy in both the adjuvant and metastatic phases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
Primary CompletionFeb 2017
First PostedJul 2020
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartJun 25, 2015
Primary CompletionFeb 8, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.0 years ago
Interventions
Pazopanibdrug